FY2022 · ended Dec 31, 2022 · Revenue $486,559, +3130.4% YoY · Filed Mar 29, 2024
Pasithea Therapeutics Corp. (KTTA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$486,559
+3130.4% vs prior year
Net income
$-20.43M
-46.9% vs prior year
Operating cash flow (TTM)
$-17.78M
Free cash flow
$-14.67M
-359.0% vs prior year
EPS
$-2.91
-592.9% vs prior year
Dividend per share
None
Shares outstanding
24.94M
+821.9% vs prior year
Net cash
$16.25M
FY 2023
Operating margin
-2587.3%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KTTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841330
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $486,559 | $15,062 |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M |
| Diluted EPS | -$2.91 | — | -$0.42 | -$1.76 | — |
| Operating cash flow | -$15.2M | — | — | -$14.6M | -$3.2M |
| Free cash flow | — | — | — | -$14.7M | -$3.2M |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M |
| Stockholders' equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M |
| Cash and investments | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M |
| Total debt | — | — | $81,680 | $504,383 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Aug 7, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 344 Pasithea Therapeutics Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.